Media & Investors

Corporate Profile

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients.

Stock Quote

Volume:

Copyright Nasdaq. Minimum 15 minutes delayed.

In the Media

May 13, 2020
Source
News of Calithera’s planned clinical trial evaluating candidate CB-280 in people with cystic fibrosis is highlighted by Cystic Fibrosis News Today.
Oct 18, 2019
Source
Calithera is highlighted by San Francisco Business Times among notable biotechs who raised funds in June of 2019.

Upcoming Events

More events are coming soon.